Ligand Pharmaceuticals Incorporated (LGND)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Ligand Pharmaceuticals Incorporated (LGND) is up 23.1% since the beginning of the year. At $233 per share, LGND is trading 5.9% below its 52-week high of $247. Investors who bought $1,000 worth of LGND shares 5 years ago would now be looking at an investment worth $2,059.

Ligand Pharmaceuticals Incorporated (LGND) has returned 23.11% so far this year and 129.00% over the past 12 months. Over the last ten years, LGND has returned 7.02% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.

Based on dividend-adjusted daily data since Nov 18, 1992, LGND's average daily return is +0.14%, while the average monthly return is +2.63%. At this rate, an investment would double in approximately 2.2 years.

Historically, 53% of months were positive and 47% were negative. The best month was Nov 2010 with a return of +421.0%, while the worst month was Aug 1998 at -48.3%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 7 months.

On a daily basis, LGND closed higher 48% of trading days. The best single day was Nov 22, 2010 with a return of +444.1%, while the worst single day was Aug 3, 2004 at -39.8%.

Ligand Pharmaceuticals Incorporated has an annualized alpha of 26.09%, beta of 1.24, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since November 19, 1992.

• This stock captured 138.74% of S&P 500 Index gains and 128.48% of its losses - amplifying both gains and losses, but participating more in upside than downside.
• R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

LGND ranks 95 for risk / return — in the top 95% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Ligand Pharmaceuticals Incorporated (LGND) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Ligand Pharmaceuticals Incorporated. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Ligand Pharmaceuticals Incorporated was 93.34%, occurring on Nov 19, 2008. Recovery took 838 trading sessions.

The current Ligand Pharmaceuticals Incorporated drawdown is 15.20%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Ligand Pharmaceuticals Incorporated over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Ligand Pharmaceuticals Incorporated is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.